Print Email

MASCC/ISOO 2016 Annual Meeting Webcasts
June 23-25, Adelaide, Australia


 GO TO 2016 MASCC/ISOO Annual Meeting webcasts

 Jump to Friday, June 24th

 Jump to Saturday, June 25th

Thursday, June 23rd

Workshop 1: Mucositis research workshop

  • 2016 MUCOSITIS NEWS - LITERATURE HIGHLIGHTS - Paolo Bossi, Italy 
  • ANIMAL MODELS FOR ORAL MUCOSITIS – FROM HAMSTER CHEEK POUCH TO MTOR-INH. ASSOCIATED STOMATITIS MODEL - Stephen T. Sonis, USA 
  • NALOXONE ADMINISTRATION IS ASSOCIATED WITH INCREASED TUMOUR GROWTH FOLLOWING IRINOTECAN IN A RAT BREAST CANCER MODEL - J. Bowen, Australia 
  • NEURON AND GLIAL CHANGE IS ASSOCIATED WITH IRINOTECAN-INDUCED MUCOSITIS IN A TUMOUR BEARING DA RAT MODEL - Daniel Thorpe, Australia 
  • TNF-? INHIBITOR ETANERCEPT DOES NOT ALTER THE SEVERITY OF METHOTREXATE-INDUCED GASTROINTESTINAL MUCOSITIS IN THE RAT - N. Kuiken, Netherlands 
  • OPEN DISCUSSION - Wim Tissing, Netherlands 
  • IS CRYOTHERAPY BENEFICIAL IN REDUCING THE INCIDENCE OF ORAL MUCOSITIS DURING AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN LYMPHOMA RECEIVING HIGH DOSE MELPHALAN? - J. Toro, USA 
  • POTENTIAL OF ST-617 TO PREVENT THE OCCURRENCE AND REDUCE THE DURATION OF SEVERE ORAL MUCOSITIS - B. Framroze, India 
  • HANGESHASHINTO PREVENTS ORAL MUCOSITIS UNDER CHEMORADIOTHERAPY TO HEAD AND NECK CANCER - T. Tamahara, Japan 
  • SINGLE NUCLEOTIDE POLYMORPHISM (SNP) OF TAC 1 GENE IN PATIENTS EXPOSED TO RADIATION THERAPY FOR HEAD AND NECK CANCERS - S. PS, Kingdom of Saudi Arabia 
  • PHOTOBIOMODULATION – CURRENT SCIENCE AND ITS APPLICATION FOR ORAL MUCOSITIS - Praveen Arany, USA 
  • EXPERT PANEL, OPEN DISCUSSION: (RACHEL GIBSON, AUSTRALIA) (STEVE SONIS, USA), (JOANNE BOWEN, AUSTRALIA), (PRAVEEN ARANY, USA), (PAOLO BOSSI, ITALY) - Panel

 Workshop 3: Supportive care and Immunotherapy

  • IMMUNE CHECKPOINT INHIBITORS AND ANTI PD1 ANTIBODIES IN CANCER THERAPY: MALIGNANT MELANOMA, NSCLC AND BEYOND - Bernardo L. Rapoport, South Africa
  • ORAL COMPLICATIONS OF IMMUNOTHERAPY - Joel Epstein, USA
  • SKIN COMPLICATIONS ASSOCIATED WITH IMMUNOTHERAPY - Vincent Sibaud, France
  • IMMUNE RELATED INFECTIONS, NEUROLOGICAL, ENDOCRINE AND PULMONARY ADVERSE EVENTS - Jean Klastersky, Belgium
  • OTHERS: UVITIS, COLITIS, HEPATIC AND OTHER GI IMMUNE RELATED ADVERSE EVENTS ASSOCIATED WITH ANTI CTL4 AND ANTI PD1 ANTIBODIES - Ronwyn van Eeden, South Africa
  • IMMUNE THERAPY IN THE ELDERLY - Matti Aapro, Switzerland

Workshop 4: End of life: Global care, local solutions

  • WHAT IS A GOOD DEATH? - Andrew Davies, United Kingdom 
  • PROGNOSTICATION IN ADVANCED CANCER PATIENTS - David Hui, USA 
  • ADVANCE CARE PLANNING - Teresa Burgess, Australia 
  • MANAGEMENT OF SYMPTOMS AT END-OF-LIFE - Mellar Davis, USA 
  • MODELS OF EOLC IN HOSPITAL - Dorothy M. K. Keefe, Australia 
  • PROVISION OF END OF LIFE CARE FOR ABORIGINAL PEOPLES - Sally Banfield, Australia 
  • PSYCHOLOGICAL IMPACT ON HEALTHCARE PROFESSIONALS OF CARING FOR DYING PATIENTS - Gregory Crawford, Australia

Workshop 6: Nutritional care throughout the advanced cancer journey

  • MANAGEMENT OF NUTRITIONAL AND HYDRATION ISSUES IN THE LAST DAYS/WEEKS OF LIFE - David Hui, USA
  • KEY PUBLICATIONS ON NUTRITIONAL ISSUES: A YEAR IN REVIEW - Mellar Davis, USA
  • SUMMARY AND NEXT STEPS - Liz Isenring, Australia

Educational Session: How to write a manuscript for supportive care in cancer

  • THE EDITORS VIEW Fredrick Ashbury, Canada 
  • THE AUTHOR'S VIEW Ian Olver, Australia 
  • THE REVIEWER'S VIEW Jørn Herrstedt, Denmark 
  • CONCLUSION Fredrick Ashbury, Canada

Opening Ceremony

  • WELCOME FROM PRESIDENT - Ian Olver, Australia 
  • OPENING BY THE GOVERNOR OF SOUTH AUSTRALIA: HIS EXCELLENCY THE HONOURABLE HIEU VAN LE AO - Hieu Van 
  • WORDS FROM MEETING CO-CHAIR: Dorothy M. K. Keefe, Australia 
  • ISOO WELCOME: Ourania Nicolatou-Galitis, Greece 
  • PRESIDENTIAL ADDRESS AND DISTINGUISHED SERVICE AWARD PRESENTATION: Ian Olver, Australia

Plenary 1: 25 Years of MASCC and future

  • FOUNDING MASCC AND THE EARLY YEARS - Jean Klastersky, Belgium 
  • AN OVERVIEW OF MASCC’S STORY AND SUCCESSES BY THE PAST PRESIDENTS OF MASCC - Matti Aapro, Switzerland 
  • AN OVERVIEW OF MASCC’S STORY AND SUCCESSES BY THE PAST PRESIDENTS OF MASCC - Paul Hesketh, USA 
  • AN OVERVIEW OF MASCC’S STORY AND SUCCESSES BY THE PAST PRESIDENTS OF MASCC - Jørn Herrstedt, Denmark 
  • AN OVERVIEW OF MASCC’S STORY AND SUCCESSES BY THE PAST PRESIDENTS OF MASCC - Dorothy M. K. Keefe, Australia 
  • AN OVERVIEW OF MASCC’S STORY AND SUCCESSES BY THE PAST PRESIDENTS OF MASCC - Dave Warr, Canada 
  • THE NEXT 25 YEARS OF SUPPORTIVE CARE AND MASCC - Stephen T. Sonis, USA

Parallel 01: Disparities in supportive care in cancer

  • DISPARITIES. DISPARITIES IN SUPPORTIVE CARE IN PAPUA NEW GUINEA - Dadi Toka, Papua New Guinea 
  • DISPARITIES IN SUPPORTIVE CARE IN INDIA - Raju Chacko, India

Parallel 02: Is e-communication critical to the delivery of cancer care?

  • WHAT MIGHT E-COMMUNICATION BEST PRACTICE INVOLVE - Phyllis Butow, Australia
  • TELEMEDICINE IN RURAL AND REMOTE AUSTRALIA - OUTREACH AND DISPARITY - Ian Olver, Australia
  • TEXT MESSAGES TO EDUCATE, ENGAGE, AND MOTIVATE (TEEM TRIAL): PATIENT PERCEPTIONS OF TEXT MESSAGING TO SUPPLEMENT PATIENT COUNSELING AND IMPROVE MEDICATION ADHERENCE - Soha Ahrari, Canada

Parallel 03: Care of cancer survivors – putting evidence into practice

  • THE SOUTH AUSTRALIAN SURVIVORSHIP FRAMEWORK - Tracey Doherty , Australia
  • DEVELOPING A SURVIVORSHIP MONITORING TOOL FOR SOUTH AUSTRALIA - Marion Eckert, Australia
  • THE HEALTHY LIVING AFTER CANCER PARTNERSHIP PROJECT - Amanda Robertson, Australia
  • PATIENT REPORTED RANKING OF LATE SYMPTOMS AFTER BREAST AND PROSTATE CANCER AND THEIR INFLUENCE ON SELF INITIATED NUTRITIONAL THERAPIES – THE BEDFORD REAL WORLD STUDY - Robert Thomas, United Kingdom
  • THE IMPACT OF CHEMOTHERAPY ON COGNITIVE FUNCTION: A PROSPECTIVE, LONGITUDINAL COHORT STUDY IN TESTICULAR CANCER - Hayley Whitford, Australia

Parallel 04: Young investigator Award Session

  • HIGH SENSITIVE CARDIAC TROPONIN T ASSAY CAN RELIABLY PREDICT EARLY ANTHRACYCLINE AND TRASTUZUMAB CARDIOTOXICITY IN BREAST CANCER PATIENTS Hiromitsu Kitayama, Japan 
  • TOLL-LIKE RECEPTOR 4 (TLR4)-MEDIATED TIGHT JUNCTION DISRUPTION AND DYSREGULATED ION SECRETION ARE KEY DRIVERS OF IRINOTECAN-INDUCED DIARRHOEA Hannah Wardill, Australia 
  • FRACTIONATED RADIATION INDUCES DIFFERENTIAL EXPRESSION OF MATRIX METALLOPROTEINASES IN THE COLON Romany Stansborough, Australia 
  • DIFFERENTIATION OF GASTROINTESTINAL TOXICITY ASSOCIATED WITH DIFFERENT NANOPARTICLE FORMULATIONS IN A MALE SPRAGUE DAWLEY RAT 5-FLUROURACIL-INDUCED MUCOSITIS MODEL Daniel Thorpe, Australia 
  • A PROSPECTIVE STUDY VALIDATING THE EORTC QLQ–BM22 BONE METASTASES MODULE IN PATIENTS WITH PAINFUL BONE METASTASES Srinivas Raman, Canada 
  • EFFICACY OF OMEGA-3 (O-3) SUPPLEMENTATION VERSUS OMEGA-6 (O-6) SUPPLEMENTATION FOR REDUCING CANCER-RELATED FATIGUE AMONG BREAST CANCER SURVIVORS: A URCC NCORP RANDOMIZED CONTROLLED TRIAL Luke Peppone, USA MICROBIAL BIOMARKERS OF ORAL MUCOSITIS ONSET Rebeca Vasconcelos, USA 
  • IMPROVING DELIVERY AND DOCUMENTATION OF SUPPORTIVE CARE MANAGEMENT OF CANCER PATIENT IN RESOURCE-CONSTRAINED DEVELOPING COUNTRIES Vinay Kumar Ramaiah, India

Parallel 29:Making Meaning, making special: a multi-media exploration of the role of the arts in cancer care

  • MAKING MEANING, MAKING SPECIAL: A MULTI-MEDIA EXPLORATION OF THE ROLE OF THE ARTS IN CANCER CARE - Sally Francis, Australia
  • MAKING MEANING, MAKING SPECIAL: A MULTI-MEDIA EXPLORATION OF THE ROLE OF THE ARTS IN CANCER CARE - Christine Putland, Australia
  • MAKING MEANING, MAKING SPECIAL: A MULTI-MEDIA EXPLORATION OF THE ROLE OF THE ARTS IN CANCER CARE - John Blines, Australia 

Parallel 05: Supportive care from the patient expert perspective

  • VIEW FROM THE BOTH SIDES OF THE ROOM - Mark Schubert, USA 
  • R-CHOP NOT SO EASY ON THE RECEIVING SIDE - Ian Hewson, Australia 
  • MANAGING LIVING WITH CANCER - Pam Nielsen, Australia 
  • FEASIBILITY, ACCEPTABILITY AND IMPACT OF A PRO-ACTIVE TELEPHONE-BASED INTERVENTION TO IMPROVE TOXICITY MANAGEMENT DURING CHEMOTHERAPY FOR EARLY STAGE BREAST CANCER - Monika Krzyzanowska, Canada 
  • PATIENT REPORTED OUTCOME MEASUREMENT: SYSTEMATIC SYMPTOM ASSESSMENT IN CANCER CARE - ONTARIO HEALTHCARE PROFESSIONALS' ATTITUDES, THE EDMONTON SYMPTOM ASSESSMENT SYSTEM (ESAS) AND THE ROAD AHEAD - Monika Krzyzanowska, Canada

Parallel 06: Maintaining bone health in cancer (Bone Study Group)

  • CANCER BONE MICROENVIRONMENT: HOW TO MAINTAIN AND HOW TO IMPROVE AN ONGOING CHALLENGE - Winston Tan, USA
  • OSTEONECROSIS POST CANCER THERAPY - Alastair Goss, Australia
  • NEW TREATMENTS FOR CHEMOTHERAPY-INDUCED BONE LOSS - Cory Xian, Australia
  • PERSONALIZATION SUPPORTIVE CARE (CORRECTION OF ANEMIA, NEUTROPENIA, AND THE APPOINTMENT OF BONE-MODIFYING AGENTS) - Anton Snegovoy, Russia
  • MEDICATION-RELATED OSTEONECROSIS OF THE JAW IN ADVANCED CANCER PATIENTS: A MULTICENTER CASE REGISTRY STUDY - Deborah P. Saunders, Canada

Parallel 07: Oral Proffered Papers

  • HOW DO I DO THAT AGAIN? VODCASTS FOR PATIENTS WITH FEEDING TUBES AND SWALLOWING DIFFICULTIES - Jenelle Loeliger, Australia
  • COMPARING PERSPECTIVES OF MEN WITH PROSTATE CANCER AND HEALTH CARE PROFESSIONALS ABOUT ACTIVE SURVEILLANCE - Margaret Fitch, Canada
  • THE IMPACT OF AN EDUCATIONAL PROGRAM ON PATIENT PRACTICES ON SAFE USE, STORAGE, AND DISPOSAL OF OPIOIDS IN A COMPREHENSIVE CANCER CENTER - Maxine de la cruz, USA
  • RESULTS OF EDUCATIONAL PROGRAM OF SUPPORTIVE CARE IN ONCOLOGY IN RUSSIA - Anton Snegovoy, Russia
  • DEVELOPING NATIONAL INDICATORS TO MEASURE PROGRESS IN PERSON-CENTRED CANCER CARE - Margaret Fitch, Canada

Parallel 08: Systematic review: update and outcomes measures (Oral Care Study Group)

  • GUIDELINE UPDATE ON THE ORAL COMPLICATIONS IN CANCER THERAPY - Deborah P. Saunders, Canada
  • GUIDELINE UPDATE ON THE ORAL COMPLICATIONS IN CANCER THERAPY A BIT ABOUT SPIT: WHAT WE KNOW ABOUT RADIATION AND XEROSTOMIA, IMRT AND PAROTID SPARING - John Wu, Canada
  • DENTAL DISEASE AND DENTAL TREATMENT PRIOR TO HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCST): ORASTEM STUDY - Allan Hovan, Canada

Parallel 30: Managing stomatitis associated with everolimus in patients with hormone-receptor positive metastatic breast cancer

  • THE KEY TO SUCCESS: A NURSE’S PERSPECTIVE ON THE MANAGEMENT OF MIAS - Jenny Gilchrist, Australia

Friday, June 24th

Parallel 09: Nausea is the new black: innovative antiemetics

  • INTRODUCTION - Lawrence Einhorn, USA
  • INTRODUCTION TO NAUSEA - Lawrence Einhorn, USA NAUSEA AND RELATED SYMPTOMS - Alex Molasiotis, Hong Kong, China
  • NAUSEA AS THE PRIMARY ENDPOINT - Janet Hardy, Australia
  • NAUSEA AS A SYMPTOM CLUSTER - Ian Olver, Australia RESULTS OF A SURVEY OF ONCOLOGY NURSES ASSESSING PRACTICE PATTERNS FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) AND ADHERENCE TO ANTIEMETIC GUIDELINES - Rebecca Clark-Snow, USA

Parallel 10: Geriatric assessment as a supportive care strategy in older adults with cancer

  • GERIATRIC ASSESSMENT: WHY BOTHER?: - Martine Extermann, USA
  • GERIATRIC ASSESSMENT IN ONCOLOGY; HOW CAN IT BE DONE IN CLINICAL PRACTICE AND MODELS OF CARE FROM AROUND THE WORLD - Nimit Singhal, Australia
  • GERIATRIC ASSESSMENT; A NURSE LED SUPPORTIVE CARE STRATEGY - Jane Philips, Australia
  • DEVELOPMENT AND VALIDATION OF AN INSTRUMENT TO IDENTIFY CARDIOMETABOLIC PREDICTORS OF MORTALITY IN OLDER INDIVIDUALS WITH CANCER. - Bogda Koczwara, Australia

Parallel 11: Education and communication study group and palliative care study groups

  • INTRODUCTION - Fran Boyle, Australia
  • ENHANCING CANCER CONSULTATIONS - Martin Tattersall, Australia
  • COMMUNICATING CANCER RISK AND TREATMENT BENEFITS TO THE PUBLIC - Sanchia Aranda, Australia
  • HANDLING UNCERTAINTY IN CLINICAL PRACTICE - Lidia Schapira, USA
  • REFERRAL CRITERIA FOR OUTPATIENT PALLIATIVE CANCER CARE: AN INTERNATIONAL CONSENSUS - David Hui, USA
  • COMPARING PALLIATIVE CARE AND SUPPORTIVE CARE SPECIALIST BELIEFS ABOUT SPIRITUAL CARE - Megan Best, Australia

Parallel 12: Infection and immune reactions in checkpoint and PD1 inhibition (Neutropenia, Infection-Myelosuppression Study Groups)

  • IMMUNE COMPLICATIONS (EXCLUDING SKIN) ASSOCIATED WITH CHECKPOINT AND PD1 INHIBITION - Bernardo L. Rapoport, South Africa
  • DERMATOLOGICAL COMPLICATIONS WITH CHECKPOINT AND PD1 INHIBITION - Vincent Sibaud, France
  • CHARACTERIZATION OF PAN-HER TYROSINE KINASE INHIBITOR-INDUCED DIARRHEA USING A RAT MODEL - Ysabella Van Sebille, Australia Plenary 2: Gastrointestinal toxicity management
  • CHEMO- AND RADIOTHERAPY -INDUCED GASTROINTESTINAL TOXICITY - Jervoise Andreyev, United Kingdom
  • ORAL TOXICITY FOLLOWING CANCER THERAPIES - Richard Logan, Australia

Parallel 13: Dysbiosis in the gut: what is it and what does it mean for cancer patients? (Mucositis Study Group)

  • MARKERS FOR CHEMOTHERAPY INDUCED MUCOSAL BARRIER INJURY IN CANCER PATIENTS - Wim Tissing, Netherlands
  • TOLL-LIKE RECEPTOR 4 SIGNALLING: IS THIS THE COMMON BIOLOGICAL MECHANISM OF REGIMEN-RELATED TOXICITIES? - Rachel Gibson, Australia PROBIOTICS FOR PREVENTION OF RADIATION ENTEROTHERAPY: A BENCH TO BEDSIDE STORY AND CALL TO ACTION - Matthew Ciorba, USA
  • THE SELECTIVE GLUCAGON-LIKE PEPTIDE-2 (GLP-2) RECEPTOR AGONIST, ELSIGLUTIDE, IS EFFECTIVE IN INHIBITING LAPATINIB-INDUCED DIARRHOEA IN AN ESTABLISHED RAT MODEL. - Bronwen Mayo, Australia

Parallel 14: Cardiac toxicity

  • CHEMOTHERAPY-INDUCED RIGHT-SIDED CARDIAC DYSFUNCTION: IT’S NOT JUST A LEFT SIDED CARDIAC PROBLEM - Vicki Shannon, USA
  • CLINICAL ASPECTS OF CARDIOTOXICITY PREVENTION: CAN NEW UNDERSTANDING MAKE CONCERNS ABOUT CARDIOTOXICITY OBSOLETE - Edward Yeh, USA
  • PRIMARY AND SECONDARY CARDIAC EVENTS; WHY CAN WE GIVE SOME CARDIOTOXIC DRUGS FOR YEARS WITH LITTLE CONCERN - Michael Ewer, USA
  • CANCER AND CARDIO-METABOLIC ILLNESS IN ELDERLY CANCER SURVIVORS – A SECONDARY ANALYSIS OF THE AUSTRALIAN LONGITUDINAL STUDY OF AGEING - Bogda Koczwara, Australia

Parallel 15: Dyspnoea (Palliative Care and Respiratory Study Groups)

  • BEYOND OXYGEN: NON-INVASIVE VENTILATION AND HIGH FLOW OXYGEN - David Hui, USA
  • PULMONARY REHABILITATION: PROCESSES AND OUTCOMES - Vicki Shannon, USA
  • IMPACT OF ONCOLOGISTS' ATTITUDES TOWARD END-OF-LIFE CARE ON PATIENT'S ACCESS TO PALLIATIVE CARE: UNDERSTANDING TYPE I VERSUS TYPE II ONCOLOGISTS - David Hui, USA

Parallel 16: Oral Proffered Papers

  • PREVALENCE OF DEMENTIA AND MILD COGNITIVE IMPAIRMENT IN OLDER CANCER PATIENTS WITH SOLID TUMOR CANCERS - Beatrice Edwards, USA
  • MINIMAL CLINICALLY IMPORTANT DIFFERENCES IN THE EORTC QLQ-BM22 AND EORTC QLQ-C15-PAL MODULES IN PATIENTS WITH BONE METASTASES - Srinivas Raman, Canada
  • OSTEOPOROSIS, LOW BONE MASS, AND RISK FACTORS FOR FRACTURES IN OLDER CANCER PATIENTS - Beatrice Edwards, USA
  • INCIDENCE OF BONE METASTASES IN US PATIENTS WITH SOLID TUMORS - Sally Wade, USA
  • “WHAT IS THE ROLE OF COMORBIDITY, FRAILTY AND FUNCTIONAL STATUS IN TREATMENT DECISION-MAKING FOR OLDER CANCER PATIENTS AND THEIR FAMILY MEMBERS, ONCOLOGISTS, AND FAMILY PHYSICIAN?” - Martine Puts, Canada
  • POINT OF CARE CLINICAL DECISION SUPPORT FOR CANCER SYMPTOM MANAGEMENT: RESULTS OF A GROUP RANDOMIZED TRIAL. - Janet Abrahm, USA

Parallel 17: Models of nutritional care in high risk cancer groups

  • IMPLEMENTING A BEST PRACTICE MODEL OF CARE FOR NUTRITIONAL MANAGEMENT OF HEAD AND NECK CANCER: TRANSLATING EVIDENCE INTO PRACTICE - Merran Findlay, Australia
  • NUTRITIONAL RISK IN LUNG CANCER: IS MEDICAL NUTRITION THERAPY EFFECTIVE - Nicole Kiss, Australia
  • MANAGING MALNUTRITION IN CANCER: HIGHLIGHTS OF STATE-WIDE COLLABORATIONS IN VICTORIAN HEALTH SERVICES - Jenelle Loeliger, Australia
  • SKELETAL MUSCLE DEPLETION AND RELATIONSHIP TO SURVIVAL IN NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING CHEMO-RADIATION - Nicole Kiss, Australia Parallel 19: Delirium in advanced cancer: state of the science
  • PHARMACOLOGIC MANAGEMENT: AN EVIDENCE-BASED UPDATE - David Hui, USA
  • STRATEGIES FOR ONCOLOGY CLINICIANS COMMUNICATING WITH FAMILY MEMBERS: DEVELOPMENT AND DELPHI CONSENSUS EVALUATION - Phyllis Butow, Australia
  • DEXAMETHASONE FOR DYSPNEA IN CANCER PATIENTS: A DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL - David Hui, USA

Parallel 20: Gut toxicity – moving beyond the normal boundaries

  • ROLE OF YOGA IN MAINTAINING QUALITY OF LIFE (QOL) IN CANCER PATIENTS - Abhishek Shankar, India
  • PROSTATE CANCER SURVIVORS - CAN THEY ENJOY LIFE AS MEN 10 YEARS AFTER TREATMENT? PART 1 - QOL, ADT, RT, RECTAL/URINARY/SEXUAL FUNCTION, LOSS OF MASCULINITY AND SURVIVORSHIP - Jim Denham, Australia
  • COMPLEMENTARY STRATEGIES FOR MUCOSITIS MANAGEMENT - Gordon S. Howarth, Australia
  • EFFECT OF YOCAS YOGA, SLEEP AND FATIGUE ON QUALITY OF LIFE (QOL) IN FEMALE BREAST CANCER SURVIVORS - Anita Peoples, USA
  • USE OF ALTERNATIVE TREATMENT IN ADDITION TO CONVENTIONAL THERAPY AMONG DANISH CANCER PATIENTS - Kristin Ingstrup Nielsen, Denmark

Saturday, June 25th

Parallel 21: Paediatrics (Peadiatric study group)

  • RECENT PAEDIATRIC GUIDELINES DEVELOPMENT - Wim Tissing, Netherlands
  • ...AND NOW FOR THE BIGGEST CHALLENGE...IMPLEMENTATION OF GUIDELINES INTO PRACTICE - Faith Gibson, United Kingdom
  • ASSESSMENT OF INVISIBLE FINANCIAL BURDEN FACED BY FAMILIES WITH CANCER CHILDREN IN INDIA - Aurosri Ramachandran, India

Parallel 22: Oral Proffered Papers

  • ROLE OF BENZYDAMINE HYDROCHLORIDE IN PREVENTION OF ORAL MUCOSITIS IN HEAD AND NECK CANCER PATIENTS TREATED WITH RADIOTHERAPY (>50 GRAY) WITH OR WITHOUT CHEMOTHERAPY - Madhup Rastogi, India
  • THE IMPACT OF A SIMPLIFIED DOCUMENTATION METHOD FOR THE EDMONTON CLASSIFICATION SYSTEM FOR CANCER PAIN (ECS-CP) ON CLINICIAN UTILIZATION - Kimberson Tanco, USA
  • THE DEGREE OF CONCORDANCE ON END-OF-LIFE CARE DECISIONS USING THE KOREAN ADVANCE DIRECTIVES AMONG CANCER PATIENT-CAREGIVER DYADS - Su-Jin Koh, Republic of Korea
  • EVALUATING THE UTILITY OF THE QUAL-EC IN THE CLINICAL CARE OF PATIENTS WITH ADVANCED CANCER - Anne Wilkinson, Australia

Parallel 23: Toxicity of combined chemotherapy and radiotherapy

  • LUNG - David Ball, Australia
  • PROSTATE CANCER SURVIVORS - CAN THEY ENJOY LIFE AS MEN 10 YEARS AFTER TREATMENT? PART 2 - QOL, URINARY INCONTINENCE/DEPRESSION AND RESILIENCE, FADE SURVIVORSHIP SCORER - Jim Denham, Australia
  • PROSTATE CANCER SURVIVORS - CAN THEY ENJOY LIFE AS MEN 10 YEARS AFTER TREATMENT? PART 2 - QOL, URINARY INCONTINENCE/DEPRESSION AND RESILIENCE, FADE SURVIVORSHIP SCORER - Vicky Bitsika, Australia
  • NORMAL TISSUE COMPLICATIONS IN COMBINED CHEMO-RADIOTHERAPY FOR HEAD AND NECK CANCERS - A MODELLING APPROACH. - Eva Bezak, Australia
  • IDENTIFICATION OF BIOMARKERS OF CHEMORADIOTHERAPY-INDUCED TOXICITY IN UPPER GASTROINTESTINAL CANCERS - Imogen Ball, Australia
  • HEAD AND NECK - Barbara Murphy, USA

Parallel 24: Fatigue and Cachexia

  • THE IMPACT OF CANCER ASSOCIATED INFLAMMATION ON CACHEXIA, CANCER PROGNOSIS AND OUTCOMES - Stephen Clarke, Australia
  • EXERCISE PRESCRIPTION FOR CANCER-RELATED FATIGUE: WHAT'S THE OPTIMAL DOSE? - Karen Mustian, USA
  • IS THERE A ROLE FOR PSYCHOSTIMULANTS IN THE MANAGEMENT OF CRF - Fausto Roila, Italy
  • PERSONALIZED THERAPY IN CRF: TARGETING MECHANISMS, ROLE OF CORTICOSTEROIDS, COGNITIVE BEHAVIORAL THERAPY OR COMBINATION THERAPY - Sriram Yennu, USA
  • FATIGUE IS ASSOCIATED WITH IMPAIRMENTS IN INSTRUMENTAL ACTIVITIES OF DAILY LIVING (IADL) AND DECREASED PHYSICAL PERFORMANCE IN OLDER CANCER PATIENTS - Charles Kamen, USA

Parallel 25: Thinking and talking about survival time in advanced cancer

  • UPDATE ON PATIENT PREFERENCES FOR PROGNOSTIC INFORMATION - Phyllis Butow, Australia
  • TEACHING COMMUNICATION SKILLS REGARDING PROGNOSIS TO AUSTRALIAN ONCOLOGY TRAINEES - Fran Boyle, Australia
  • USING A WEB-BASED TOOL TO ESTIMATE AND EXPLAIN 3 SCENARIOS FOR SURVIVAL TIME TO PATIENTS WITH ADVANCED CANCER - Belinda Kiely, Australia
  • AN INVESTIGATION OF THE CONCORDANCE BETWEEN PATIENTS AND THEIR NON-PROFESSIONAL CARERS ABOUT FACTORS ASSOCIATED WITH A “GOOD DEATH” AND OTHER IMPORTANT END-OF-LIFE DECISIONS - Andrew Davies, United Kingdom

Parallel 26: Oral Proffered Papers

  • NEUROPHYSIOLOGICAL CHANGES ASSOCIATED WITH SUNITINIB FATIGUE SEVERITY - Mellar Davis, USA
  • PATIENT INITIATED MENTORING PROGRAM IN KIDNEY CANCER: PRELIMINARY OUTCOMES - Winston Tan, USA
  • QUALITY OF LIFE, EFFICACY AND PATIENT-REPORTED OUTCOME WITH NEPA AS CINV PROPHYLAXIS IN HIGHLY OR MODERATELY EMETOGENIC CHEMOTHERAPY - Petra Feyer, Germany
  • ROLAPITANT FOR CONTROL OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS WITH LUNG CANCER - Rudolph Navari, USA
  • ROLAPITANT FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS WITH BREAST CANCER - Lee Schwartzberg, USA
  • INFORMED CONSENT IN CANCER CARE - A STUDY OF VICTORIAN PATIENTS' EXPERIENCES - Deborah Lawson, Australia
  • SUBGROUPS OF PATIENTS WITH DISTINCT PAIN QUALITIES ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN) - Christine Miaskowski, USA

Parallel 27: Hair loss and scalp cooling: integrating state of science into practice

  • IMPLEMENTATION OF SCALP COOLING IN AUSTRALIA - Fran Boyle, Australia
  • IMPLEMENTATION OF SCALP COOLING IN THE UK - Annie Young, United Kingdom
  • EYELASH AND EYEBROW MADAROSIS: A QUALITATIVE STUDY TO ASSESS THE PERCEPTIONS AND EXPERIENCE OF AUSTRALIAN PATIENTS WITH BREAST CANCER - Kortnye Morris, Australia
  • COMFORTABLE COOLING DEVICE VERSUS NATURE - Java Walladbegi, Sweden

Parallel 28: Palliative care pain management

  • SCRAMBLER THERAPY IN MANAGING CANCER PAIN; WHAT IS THE EVIDENCE? - Charles Loprinzi, USA
  • CHEMOTHERAPY NEUROPATHY, CONDITIONED PAIN MODULATION AND THE BENEFITS OF QUANTITATIVE SENSORY TESTING AND DULOXETINE - Mellar Davis, USA
  • MANAGING PAIN IN A CANCER SURVIVOR - Paul Sloan, USA

Plenary 3: Survivorship

  • OLDER SURVIVORS: PLACING CANCER WELL AMONG OTHER HEALTH ISSUES - Martine Extermann, USA

ISOO Session 1: Oral oncology and hematopoietic bone marrow transplantations

  • INTRODUCTION, BACKGROUND (TO COLLABORATION) AND WELCOME (ISOO & EBMT) - Richard Logan, Australia
  • ORAL ONCOLOGY AND HAEMATOPOIETIC STEM CELL TRANSPLANTATION - Nicole Loft, Australia
  • ORAL ONCOLOGY AND TRANSPLANT CARE - THE DENTAL TEAM’S PERSPECTIVE - Sharon Liberali, Australia

ISOO Session 2: From silos to symptom clusters: 30 years of the ISOO

  • SYMPTOM CLUSTERS - AN ORAL ONCOLOGY PERSPECTIVE - Doug Peterson, USA
  • A MEDICAL ONCOLOGY PERSPECTIVE ON HOW UNDERSTANDING OF OUR SYMPTOMS AFFECTS MANAGEMENT OF PATIENTS - Barbara Murphy, USA
  • A RADIATION ONCOLOGY PERSPECTIVE ON HOW OUR UNDERSTANDING OF SYMPTOMS AFFECTS MANAGEMENT OF PATIENTS - John Wu, Canada

ISOO Session 3: Oral care study group guidelines update (including a launch of patient care guidelines)

  • DOES HYPERBARIC OXYGEN HAVE A ROLE IN PREVENTING OSTEORADIONECROSIS POST-RADIOTHERAPY? - Allan Hovan, Canada
  • PHOTOBIOMODULATION USING LOW LEVEL LASER THERAPY IN SUPPORTIVE CARE IN CANCER: ARE WE READY YET? - Nair Raj, Australia
  • ISOO PATIENT CARE INFORMATION - Deborah P. Saunders, Canada